î
îž
āļĨāđāļāļāļāļīāļ
î
Zai Lab Ltd
ZLAB18.000USD
+0.490+2.80%
āļāļīāļÂ 03/27, 16:00ïžETïžāļĢāļēāļāļēāļĨāđāļēāļāđāļē 15 āļāļēāļāļĩ
1.99BāļĄāļđāļĨāļāđāļēāļāļĨāļēāļ
āļāļēāļāļāļļāļP/E TTM
î
āļĢāļēāļĒāļĨāļ°āđāļāļĩāļĒāļāđāļāļīāđāļĄāđāļāļīāļĄāļāļāļ Zai Lab Ltd āļāļĢāļīāļĐāļąāļ
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
āļāđāļāļĄāļđāļĨ Zai Lab Ltd
îāļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļZLAB
āļāļ·āđāļāļāļĢāļīāļĐāļąāļZai Lab Ltd
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļSep 28, 2020
āļāļĩāļāļĩāđāļDu (Ying)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ1869
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒDepository Receipt
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļSep 28
āļāļĩāđāļāļĒāļđāđBuilding B, 899 Halei Road, Pudong
āđāļĄāļ·āļāļSHANGHAI
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻChina
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ201203
āđāļāļĢāļĻāļąāļāļāđ862161632588
āđāļ§āđāļāđāļāļāđhttps://www.zailaboratory.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļZLAB
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļSep 28, 2020
āļāļĩāļāļĩāđāļDu (Ying)
āļāļđāđāļāļĢāļīāļŦāļēāļĢāļāļĢāļīāļĐāļąāļāļāļāļ Zai Lab Ltd
îāļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Dr. John David Diekman, Ph.D.
Dr. John David Diekman, Ph.D.
Lead Independent Director
Lead Independent Director
99.77K
+10.86%
Mr. Joshua L. Smiley
Mr. Joshua L. Smiley
President, Chief Operating Officer
President, Chief Operating Officer
91.03K
+4.86%
Mr. William David (Bill) Lis
Mr. William David (Bill) Lis
Independent Director
Independent Director
35.11K
-8.50%
Dr. Yajing Chen, Ph.D.
Dr. Yajing Chen, Ph.D.
Chief Financial Officer
Chief Financial Officer
20.00K
+12.78%
Mr. Frazor Titus Edmondson, J.D.
Mr. Frazor Titus Edmondson, J.D.
Company Secretary, Chief Legal Officer
Company Secretary, Chief Legal Officer
--
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Dr. Richard B. Gaynor, M.D.
Dr. Richard B. Gaynor, M.D.
Independent Director
Independent Director
--
--
Mr. Michel Pericles Vounatsos
Mr. Michel Pericles Vounatsos
Independent Director
Independent Director
--
--
Dr. Rafael G. Amado, M.D.
Dr. Rafael G. Amado, M.D.
President, Head of Global Research and Development
President, Head of Global Research and Development
--
--
Ms. Christine Chiou
Ms. Christine Chiou
Senior Vice President, Head - Investor Relations
Senior Vice President, Head - Investor Relations
--
--
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Dr. John David Diekman, Ph.D.
Dr. John David Diekman, Ph.D.
Lead Independent Director
Lead Independent Director
99.77K
+10.86%
Mr. Joshua L. Smiley
Mr. Joshua L. Smiley
President, Chief Operating Officer
President, Chief Operating Officer
91.03K
+4.86%
Mr. William David (Bill) Lis
Mr. William David (Bill) Lis
Independent Director
Independent Director
35.11K
-8.50%
Dr. Yajing Chen, Ph.D.
Dr. Yajing Chen, Ph.D.
Chief Financial Officer
Chief Financial Officer
20.00K
+12.78%
Mr. Frazor Titus Edmondson, J.D.
Mr. Frazor Titus Edmondson, J.D.
Company Secretary, Chief Legal Officer
Company Secretary, Chief Legal Officer
--
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
āļŠāļąāļāļŠāđāļ§āļāļāļāļāļĢāļēāļĒāđāļāđ
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 6 āļĄ.āļ.
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 6 āļĄ.āļ.
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
ZEJULA
42.43M
36.78%
VYVGART
27.73M
24.03%
NUZYRA
15.43M
13.38%
Optune
12.66M
10.97%
QINLOCK
8.90M
7.72%
āļāļ·āđāļ āđ
8.21M
7.12%
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
China (Mainland)
116.09M
0.00%
āļāļēāļĄāļāļļāļĢāļāļīāļ
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļ
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
ZEJULA
42.43M
36.78%
VYVGART
27.73M
24.03%
NUZYRA
15.43M
13.38%
Optune
12.66M
10.97%
QINLOCK
8.90M
7.72%
āļāļ·āđāļ āđ
8.21M
7.12%
āļŠāļāļīāļāļīāļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 24 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 24 āļ.āļ.
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
RTW Investments L.P.
6.17%
Norges Bank Investment Management (NBIM)
3.41%
Frazier Life Sciences Management, L.P.
1.69%
ClearBridge Investments, LLC
1.60%
UBS Financial Services, Inc.
1.58%
āļāļ·āđāļ āđ
85.56%
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
RTW Investments L.P.
6.17%
Norges Bank Investment Management (NBIM)
3.41%
Frazier Life Sciences Management, L.P.
1.69%
ClearBridge Investments, LLC
1.60%
UBS Financial Services, Inc.
1.58%
āļāļ·āđāļ āđ
85.56%
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
Investment Advisor/Hedge Fund
11.87%
Investment Advisor
7.07%
Hedge Fund
4.21%
Sovereign Wealth Fund
3.41%
Individual Investor
1.90%
Private Equity
1.69%
Research Firm
1.50%
Venture Capital
0.25%
Pension Fund
0.05%
āļāļ·āđāļ āđ
68.06%
āļāļēāļĢāļāļ·āļāļŦāļļāđāļāļāļāļāļŠāļāļēāļāļąāļ
îāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļļāļāļāļĩāđ 21 āļĄ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļļāļāļāļĩāđ 21 āļĄ.āļ.
āļāđāļ§āļāđāļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļāļēāļ
āļāļģāļāļ§āļāļŠāļāļēāļāļąāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
2026Q4
280
37.42M
42.38%
--
2025Q4
370
44.73M
39.84%
-12.84M
2025Q3
372
46.61M
41.70%
-15.37M
2025Q2
394
60.58M
54.15%
-11.96M
2025Q1
453
59.51M
53.68%
-14.18M
2024Q4
446
60.80M
55.47%
-4.29M
2024Q3
439
51.45M
51.99%
-10.14M
2024Q2
454
47.04M
47.66%
-14.67M
2024Q1
465
46.22M
46.47%
-13.77M
2023Q4
497
46.31M
46.92%
-16.57M
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļīāļāļāļĢāļĢāļĄāļāļđāđāļāļ·āļāļŦāļļāđāļ
îāļāļ·āđāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
āđāļāļĨāļĩāđāļĒāļ%
āļ§āļąāļāļāļĩāđ
RTW Investments L.P.
2.29M
2.05%
-3.25M
-58.62%
Sep 30, 2025
Frazier Life Sciences Management, L.P.
1.63M
1.45%
+319.18K
+24.40%
Sep 30, 2025
ClearBridge Investments, LLC
3.52M
3.14%
-492.62K
-12.28%
Sep 30, 2025
Citadel Advisors LLC
987.04K
0.88%
+620.83K
+169.53%
Sep 30, 2025
Fidelity Management & Research Company LLC
4.28M
3.82%
-610.67K
-12.50%
Sep 30, 2025
Baron Capital Management, Inc.
1.37M
1.22%
-216.57K
-13.64%
Sep 30, 2025
Adar1 Capital Management LLC
868.78K
0.78%
+18.34K
+2.16%
Sep 30, 2025
Du (Ying Samantha)
917.98K
0.82%
+74.14K
+8.79%
Dec 11, 2025
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
ETF āļāļĩāđāđāļāļĩāđāļĒāļ§āļāđāļāļ
îāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāđāļŠāļēāļĢāđāļāļĩāđ 6 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāđāļŠāļēāļĢāđāļāļĩāđ 6 āļ.āļ.
āļāļ·āđāļ
āļŠāļąāļāļŠāđāļ§āļ
Tema Oncology ETF
1.67%
ALPS Medical Breakthroughs ETF
1.19%
Virtus LifeSci Biotech Products ETF
0.97%
Invesco Golden Dragon China ETF
0.58%
National Security Emerging Markets Index ETF
0.39%
iShares Biotechnology ETF
0.18%
Capital Group New Geography Equity ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
ActivePassive International Equity ETF
0.03%
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Tema Oncology ETF
āļŠāļąāļāļŠāđāļ§āļ1.67%
ALPS Medical Breakthroughs ETF
āļŠāļąāļāļŠāđāļ§āļ1.19%
Virtus LifeSci Biotech Products ETF
āļŠāļąāļāļŠāđāļ§āļ0.97%
Invesco Golden Dragon China ETF
āļŠāļąāļāļŠāđāļ§āļ0.58%
National Security Emerging Markets Index ETF
āļŠāļąāļāļŠāđāļ§āļ0.39%
iShares Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.18%
Capital Group New Geography Equity ETF
āļŠāļąāļāļŠāđāļ§āļ0.15%
ProShares Ultra Nasdaq Biotechnology
āļŠāļąāļāļŠāđāļ§āļ0.12%
Invesco Nasdaq Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.12%
ActivePassive International Equity ETF
āļŠāļąāļāļŠāđāļ§āļ0.03%
āđāļāļīāļāļāļąāļāļāļĨ
îāļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
āļ§āļąāļāļāļĩāđ
āđāļāļīāļāļāļąāļāļāļĨ
āļ§āļąāļāļāļĩāđāļāļąāļāļāļķāļ
āļ§āļąāļāļāļĩāđāļāļģāļĢāļ°āđāļāļīāļ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļāļēāļĢāđāļāđāļāļŦāļļāđāļ
îāļ§āļąāļāļāļĩāđ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļ§āļąāļāļāļĩāđ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
